Melatonina

Target

Cerca gli articoli con queste parole nel campo target

Azione della melatonina

Cerca gli articoli con riferimento a queste azioni della melatonina

Anno: 1994

Titolo: Differences between pulsatile or continuous exposure to melatonin on MCF-7 human breast cancer cell proliferation

Riferimento:
Cancer Lett. 1994 Sep 30;85(1):105-9.

Azione della melatonina:
Antiproliferative effect was obtained by sequential exposure to 10(-9) M/10(-11)M 12/12h melatonin, which mimics the physiological rhythm of serum melatonin concentration.

Target:
Physiological rhythm/serum melatonin concentration
Titolo: Melatonin modulates growth factor activity in MCF-7 human breast cancer cells

Riferimento:
J Pineal Res. 1994 Aug;17(1):25-32.

Azione della melatonina:
Melatonin(10(-9)M) may inhibit the action and/or release of growth stimulatory factors as well as stimulate the release of growth inhibitory factors.

Target:
Epidermal growth factor (EGF)
Titolo: Breast cancer mortality among female electrical workers in the United States

Riferimento:
J Natl Cancer Inst. 1994 Jun 15;86(12):921-5.

Azione della melatonina:
Exposure to extremely low-frequency electromagnetic fields reduces the production of melatonin.

Target:
ELF
Titolo: Diminished pineal function coincides with disturbed circadian endocrine rhythmicity in untreated primary cancer patients. Consequence of premature aging or of tumor growth?

Riferimento:
Ann N Y Acad Sci. 1994 May 31;719:502-25. Review.

Azione della melatonina:
No abstract available.

Target:
No abstract available.
Titolo: 5-Fluorouracil attenuates an oncostatic effect of melatonin on estrogen-sensitive human breast cancer cells (MCF7)

Riferimento:
Cancer Lett. 1994 Jun 15;81(1):95-8.

Azione della melatonina:
Melatonin(0,3nM)inhibited MCF7 cell growth, effect of melatonin was reduced by the co-administration of 5-FU.

Target:
5-fluorouracil (5-FU)

Anno: 1995

Titolo: Efficacy and tolerability of cancer neuroimmunotherapy with subcutaneous low-dose interleukin-2 and the pineal hormone melatonin - a progress report of 200 patients with advanced solid neoplasms

Riferimento:
Oncol Rep. 1995 Nov;2(6):1063-8.

Azione della melatonina:
Induce objective tumor regressions in most advanced solid tumor histotypes by low-dose IL-2 plus MLT (orally at 40 mg/day).

Target:
Interleukin-2 (IL.2)
Titolo: Serum melatonin in multiple myeloma: natural brake or epiphenomenon?

Riferimento:
Anticancer Res. 1995 Nov-Dec;15(6B):2633-7.

Azione della melatonina:
Patients with multiple myeloma showed significantly higher mean melatonin serum levels, increased secretion might be considered as a compensatory mechanism of regulating neoplastic growth.

Target:
Antineoplastic activity.
Titolo: The nuclear receptor for melatonin represses 5-lipoxygenase gene expression in human B lymphocytes

Riferimento:
J Biol Chem. 1995 Mar 31;270(13):7037-40.

Azione della melatonina:
Melatonin is a natural ligand of RZR alpha and RZR beta, down-regulating the expression of 5-lipoxygenase about 5-fold in B-Lymphocytes.

Target:
Retinoid Z receptor (RZR alpha and beta).
Titolo: A randomized study of tamoxifen alone versus tamoxifen plus melatonin in estrogen receptor-negative heavily pretreated metastatic breast-cancer patients

Riferimento:
Oncol Rep. 1995 Sep;2(5):871-3.

Azione della melatonina:
Association of MLT(20 mg/day orally) may make TMX effective also in ER-negative metastatic breast cancer patients.

Target:
Tamoxifen (TMX) Melatonin(MLT) Estrogen receptor (ER)
Titolo: Melatonin inhibition of MCF-7 human breast-cancer cells growth: influence of cell proliferation rate.

Riferimento:
Cancer Lett. 1995 Jul 13;93(2):207-12.

Azione della melatonina:
Direct relation between proliferative rate of cells and melatonin (10(-9)M) actions on MCF-7 cells.

Target:
Inhibitory actions on cell growth

A.I.A.N. - Modena

Melatonina

Anno: 1994

Anno: 1995

Pagine